Inozyme Secures $270M to Propel Groundbreaking Rare Disease Therapeutics with INZ-701

In a groundbreaking development that underscores its commitment to transforming rare disease treatment, Inozyme, a pioneering clinical-stage biopharmaceutical company, has successfully raised $270 million in its latest funding round. This significant investment not only reinforces confidence in Inozyme’s innovative approach but also accelerates the clinical development of its lead candidate, INZ-701. INZ-701 is a revolutionary ENPP1 Fc fusion protein enzyme replacement therapy (ERT) that works by increasing levels of PPi and adenosine, two critical metabolites whose deficiencies have long been associated with severe bone and vascular conditions. By targeting the PPi-Adenosine Pathway, this therapy aims to correct pathological mineralization and intimal proliferation, thereby addressing some of the most challenging aspects of diseases such as ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. The funds raised will be strategically allocated to advance clinical trials, expand research efforts, and enhance the overall development scope to unlock new therapeutic avenues for patients impacted by these devastating conditions. As a company dedicated to leveraging cutting-edge science to develop life-changing treatments, Inozyme is set to push the boundaries of traditional biopharmaceutical research. This funding announcement marks a pivotal moment in the company’s journey, providing the critical resources necessary to fast-track clinical studies and expedite the regulatory review processes. Overall, the investment reflects a strong endorsement of Inozyme’s vision and reinforces its leading position in the race to innovate new therapeutics for rare diseases that affect bone health and blood vessel function, paving the way for improved outcomes and a renewed hope for patients worldwide.